GSK plans bid to shareholders to acquire HGS for $2.6 billion

GlaxoSmithKline will continue pursuit of Human Genome Sciences with an offer of $2.6 billion, or $13 per share, after HGS rej -More- …
Read the full story: BIO SmartBrief